Regeneron Pharmaceuticals Balance Sheet

REGN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)

Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.

Regeneron Pharmaceuticals had $40.6B in total assets and $31.3B in shareholders' equity as of FY2025. Total debt was $2.0B against $3.1B in cash, resulting in a $1.1B net cash position.

Based on SEC 10-K filings.

Key Data Points

Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
Strong profit margin: 32.1%

Data sourced from SEC EDGAR filings. Not investment advice.

Item	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Cash & Equivalents	$3.1B	$2.5B	$2.7B	$2.9B	$2.2B	$1.6B	$1.6B	$1.5B	$812.7M	$535.2M	$809.1M	$648.7M	$483.6M	$230.3M	$207.1M
Accounts Receivable	$5.7B	$6.2B	$5.7B	$5.3B	$6.0B	$3.1B	$2.1B	$1.7B	$1.5B	$1.3B	$1.2B	$739.4M	$787.1M	$593.2M	$28.3M
Inventory	$3.2B	$3.1B	$2.6B	$2.4B	$2.0B	$1.9B	$1.4B	$1.2B	$726.1M	$399.4M	$238.6M	$128.9M	$70.4M	$28.6M	-
Current Assets	$18.0B	$18.7B	$19.5B	$15.9B	$14.0B	$9.8B	$7.7B	$6.4B	$4.3B	$3.2B	$2.9B	$2.1B	$1.8B	$1.2B	$652.9M
PP&E (Net)	-	-	-	$3.8B	$3.5B	$3.2B	-	$2.6B	$2.4B	$2.1B	$1.6B	$974.3M	$527.0M	$379.9M	$368.0M
Total Assets	$40.6B	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B	$14.8B	$11.7B	$8.8B	$7.0B	$5.6B	$3.8B	$3.0B	$2.1B	$1.3B
Current Liabilities	$4.4B	$3.9B	$3.4B	$3.1B	$3.9B	$2.7B	$2.1B	$1.4B	$1.1B	$1.2B	$811.2M	$654.7M	$298.8M	$163.6M	$148.3M
Total Debt	$2.0B	$2.0B	$2.0B	$2.0B	$2.0B	$2.0B	$0	-	-	-	-	-	-	-	-
Shareholders' Equity	$31.3B	$29.4B	$26.0B	$11.0B	$11.1B	$8.8B	$11.1B	$8.8B	$6.1B	$4.4B	$3.7B	$2.6B	$485.7M	$1.3B	$396.8M

Other Financial Statements

Income Statement Cash Flow Statement All Financial Data

Scores & Analysis

Piotroski F-Score Altman Z-Score Financial Ratios

Regeneron Pharmaceuticals Profile All Financial Data

Item

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

Cash & Equivalents

$3.1B

$2.5B

$2.7B

$2.9B

$2.2B

$1.6B

$1.5B

$812.7M

$535.2M

$809.1M

$648.7M

$483.6M

$230.3M

$207.1M

Accounts Receivable

$5.7B

$6.2B

$5.7B

$5.3B

$6.0B

$3.1B

$2.1B

$1.7B

$1.5B

$1.3B

$1.2B

$739.4M

$787.1M

$593.2M

$28.3M

Inventory

$3.2B

$3.1B

$2.6B

$2.4B

$2.0B

$1.9B

$1.4B

$1.2B

$726.1M

$399.4M

$238.6M

$128.9M

$70.4M

$28.6M

Current Assets

$18.0B

$18.7B

$19.5B

$15.9B

$14.0B

$9.8B

$7.7B

$6.4B

$4.3B

$3.2B

$2.9B

$2.1B

$1.8B

$1.2B

$652.9M

PP&E (Net)

$3.8B

$3.5B

$3.2B

$2.6B

$2.4B

$2.1B

$1.6B

$974.3M

$527.0M

$379.9M

$368.0M

Total Assets

$40.6B

$37.8B

$33.1B

$29.2B

$25.4B

$17.2B

$14.8B

$11.7B

$8.8B

$7.0B

$5.6B

$3.8B

$3.0B

$2.1B

$1.3B

Current Liabilities

$4.4B

$3.9B

$3.4B

$3.1B

$3.9B

$2.7B

$2.1B

$1.4B

$1.1B

$1.2B

$811.2M

$654.7M

$298.8M

$163.6M

$148.3M

Total Debt

$2.0B

Shareholders' Equity

$31.3B

$29.4B

$26.0B

$11.0B

$11.1B

$8.8B

$11.1B

$8.8B

$6.1B

$4.4B

$3.7B

$2.6B

$485.7M

$1.3B

$396.8M